Management of Eczematous Reactions Secondary to Biologic Use in Psoriasis Patients: A Retrospective Study
Authors Amara, Lopez, Kodali, Hawkins, and Stratman declare no conflicts of interest. Author Lebwohl has received research funds on behalf of Mount Sinai from: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB Inc. and is a consultant for Almirall, AltruBio Inc. AnaptysBio, Apogee, Arcutis Inc. AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, EPI, Evommune Inc. Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. Author Guttman-Yassky is an employee of Mount Sinai and has received research grants (paid to the institution) from Boehringer Ingelheim, Leo Pharma, Pfizer, Cara Therapeutics, UCB, Kyowa Kirin, RAPT, Amgen, GSK, Incyte, Sanofi, Bristol Myers Squibb, Aslan, Regeneron, Anaptysbio, Concert, and Janssen. Author Guttman-Yassky is a consultant for Abbvie, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Apollo Therapeutics Limited, Artax Biopharma Inc. AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Cara Therapeutics, Centrexion Therapeutics Corporation, Connect Biopharm, Eli Lilly, Enveda Biosciences, Escient Pharmaceuticals Inc. Fairmount Funds Management LLC, Forest Laboratories, Galderma, Gate Bio, Google Ventures (GV), GSK Immunology, Horizon Therapeutics U.S.A. Inc. Incyte, Inmagene, Janssen Biotech, JT Central Pharmaceutical Research Institute, Jasper Therapeutics, Kyowa Kirin, Leo Pharma, Merck, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, NUMAB Therapeutics AG, OrbiMed Advisors LLC, OTSUKA, Pfizer, Pharmaxis Ltd. Pioneering Medicine VII Inc. Proteologix US Inc. RAPT, Regeneron Pharmaceuticals, Ribon Therapeutics Inc. Sanofi, SATO, Schrödinger Inc. Sun Pharma Advanced Research Company (SPARC), Teva Branded Pharmaceutical Products R&D, and UCB.
Authors
- Scott Stratman (ORCID: https://orcid.org/0000-0001-7236-9454)
- Nilesh Kodali (ORCID: https://orcid.org/0000-0003-2092-9469)
- Emma Guttman‐Yassky (ORCID: https://orcid.org/0000-0002-9363-324X)
- Kelly Hawkins (ORCID: https://orcid.org/0000-0002-9281-230X)
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Mildrey Jiménez López
- S. Abu Amara (ORCID: https://orcid.org/0000-0001-9616-4285)
Institutions
- Rutgers, The State University of New Jersey (US)
- Boston University (US)
- Albert Einstein College of Medicine (US)
- Rutgers New Jersey Medical School (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1111/ijd.17727
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00